Four Months of Fingolimod Does Not Improve Anxiety or Depression in MS

Psychiatric Comorbidity in Multiple Sclerosis: The Role of Fingolimod

Fingolimod is an established oral disease-modifying therapy for relapsing-remitting multiple sclerosis, with demonstrated efficacy in reducing relapse rates and magnetic resonance imaging lesion activity compared to injectable interferon beta-1a [1]. Its use, however, requires balancing these neurological benefits against a known risk profile, including a modest increase in the incidence of respiratory and herpes virus infections [2]. Beyond its primary immunomodulatory effects, a critical question for clinicians is whether this therapy also impacts the significant burden of psychiatric comorbidities common in multiple sclerosis. Some previous analyses have suggested that a switch to fingolimod is associated with an improvement in depressive symptoms [3]. This observation has raised the possibility that the drug's benefits may extend beyond physical endpoints, prompting further investigation into its direct or indirect effects on patient mood and anxiety.

Evaluating Fingolimod in a Treatment-Naive Cohort

Anxiety and depression are highly prevalent comorbidities among patients with multiple sclerosis, often complicating clinical management and diminishing overall quality of life. Because fingolimod is an oral disease-modifying therapy that crosses the blood-brain barrier, researchers hypothesized it might offer psychological benefits in addition to its primary immunomodulatory effects. To explore this potential dual benefit, investigators conducted a prospective cohort study on 61 patients with relapsing-remitting multiple sclerosis who initiated fingolimod treatment for the first time at the Imam Reza Clinic in Shiraz, Iran. To quantify mood changes, the clinical team assessed psychological symptoms using the Hospital Anxiety and Depression Scale (a validated self-assessment tool designed to measure the severity of mood disorders in medical outpatients). The researchers administered this scale at baseline and again after four months of treatment to monitor any shifts in the psychological well-being of the cohort, aiming to provide clinicians with clearer expectations regarding the psychiatric impact of initiating this therapy.

Four-Month Outcomes on Mood and Anxiety

To determine whether the initiation of fingolimod altered psychological symptoms, the researchers utilized paired t-tests (a statistical method comparing the same patients' scores before and after treatment) to evaluate changes on the Hospital Anxiety and Depression Scale. At the four-month follow-up, the clinical data revealed no meaningful improvement in patient anxiety. Specifically, mean anxiety scores changed from 5.2 ± 4.2 at baseline to 4.9 ± 4.0 after four months of therapy. This slight reduction was not statistically significant (p = 0.50), indicating that the medication did not directly alleviate anxiety symptoms during the early treatment phase. The analysis of depressive symptoms yielded similar results, as mean depression scores changed from 5.0 ± 3.8 to 4.5 ± 3.4. As with the anxiety measures, this change was not statistically significant (p = 0.30). For practicing physicians, these findings demonstrate that initiating fingolimod does not yield rapid or direct improvements in these psychiatric measures over a short-term period. While the drug remains highly effective for its primary immunomodulatory targets, clinicians should continue to rely on dedicated psychiatric interventions, such as cognitive behavioral therapy or targeted antidepressants, to manage comorbid mood disorders in this patient population.

Baseline Predictors and Post-Treatment Modulation

To better understand the clinical context of these mood disorders, the researchers utilized logistic regression analyses (a statistical model used to determine the probability of a specific outcome based on various risk factors) to identify predictors of baseline depression. Before initiating fingolimod, specific clinical and personal factors heavily influenced patient mood. The data showed that at baseline, multiple sclerosis relapses were significantly associated with depression (odds ratio = 4.7, p = 0.02), meaning patients with recent relapses were nearly five times more likely to be depressed. Additionally, prior medication use was strongly linked to baseline depression (odds ratio = 5.9, p = 0.03). When evaluating anxiety, the investigators found that recent sad life events were significantly associated with anxiety prior to starting the new therapy. To determine if these risk factors persisted, the researchers performed an analysis of covariance (a statistical method that evaluates post-treatment outcomes by adjusting for initial baseline differences among patients) to assess post-treatment anxiety and depression. After controlling for baseline scores, no factors were significantly associated with post-treatment anxiety or depression. The initial baseline predictors, specifically relapses, prior medication use, and recent sad events, were no longer significant after treatment. For practicing physicians, this shift in risk factors offers an interesting clinical insight. The authors note that the loss of significance of baseline predictors suggests a potential treatment-related modulation of psychological effects. Even though the overall mean anxiety and depression scores did not drop significantly, the therapy may alter how external stressors and disease activity influence patient mood, perhaps by stabilizing the underlying neuroinflammatory environment. Because this cohort had relatively mild psychological symptoms at baseline, the researchers concluded that future research in patients with higher disability and more severe symptoms is warranted to fully clarify the psychiatric impact of fingolimod.

References

1. Cohen JA, Barkhof F, Comı G, et al. Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine. 2010. doi:10.1056/nejmoa0907839

2. Zhao Z, Ma C, Gu Z, Dong Y, Lv Y, Zhong M. Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.. Frontiers in immunology. 2021. doi:10.3389/fimmu.2021.611711

3. Hunter SF, Agius M, Miller DM, et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.. Journal of the neurological sciences. 2016. doi:10.1016/j.jns.2016.03.024